Related references
Note: Only part of the references are listed.Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Christopher J. L. Murray et al.
LANCET (2022)
Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey
Sara Tomczyk et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Drug repurposing for antimicrobial discovery
Maya A. Farha et al.
NATURE MICROBIOLOGY (2019)
Repurposing disulfiram for treatment of Staphylococcus aureus infections
Ritesh Thakare et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Update on drug-repurposing: is it useful for tackling antimicrobial resistance?
Grace Kaul et al.
FUTURE MICROBIOLOGY (2019)
Antibiotic resistance in Staphylococcus aureus. Current status and future prospects
Timothy J. Foster
FEMS MICROBIOLOGY REVIEWS (2017)
Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid
Katie E. Barber et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Nitazoxanide Stimulates Autophagy and Inhibits mTORC1 Signaling and Intracellular Proliferation of Mycobacterium tuberculosis
Karen K. Y. Lam et al.
PLOS PATHOGENS (2012)
Nitazoxanide Inhibits Biofilm Formation by Staphylococcus epidermidis by Blocking Accumulation on Surfaces
Florence Tchouaffi-Nana et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni
Paul S. Hoffman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)